{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T02:19:41Z","timestamp":1790734781020,"version":"4.1.0"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T00:00:00Z","timestamp":1767312000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The expanding role of transcatheter aortic valve implantation (TAVI) highlights the need to identify factors influencing long-term outcomes. Systemic inflammatory response syndrome (SIRS) is a frequent post-procedural event that may adversely affect prognosis. Measurement of inflammatory biomarkers may improve the understanding of underlying mechanisms and refine patient risk stratification.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This single-center, prospective cohort study, enrolled 62 consecutive patients undergoing TAVI, who were followed for up to 5 years. Blood samples were collected before TAVI, at 24\u2005h and 3\u20136 months post-procedure. Changes in biomarker levels, predictors of SIRS, and inflammatory predictors of long-term outcomes were analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      SIRS developed in 45% of patients. Significant temporal changes were observed in hs-CRP, TNF-\u03b1, sST2\/IL-33, IL-10, and IL-2 levels, irrespective of baseline or procedural characteristics. The development of SIRS was associated with a higher risk of all-cause mortality or unplanned hospitalization at 5 years (HR 3.07, 95% CI 1.57\u20136.00;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.001). Baseline hs-CRP (HR 1.21, 95% CI 1.09-1.35;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) and IFN-\u03b3 (HR 1.22; 95% CI 1.09\u20131.36;\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&amp;lt;\u20090.001) levels were predictive of adverse outcomes. In multivariable Cox analysis, these associations remained, though findings should be interpreted cautiously given the limited sample size.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      SIRS is a common post-TAVI phenomenon and may be linked to long-term outcomes. Elevated pre-procedural hs-CRP and IFN-\n                      <jats:italic>\u03b3<\/jats:italic>\n                      levels were associated with higher risk for adverse events, suggesting they may serve as exploratory biomarkers for risk stratification in this population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2025.1722293","type":"journal-article","created":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:29:11Z","timestamp":1767335351000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Inflammatory biomarkers as predictors of prognosis in patients after transcatheter aortic valve implantation"],"prefix":"10.3389","volume":"12","author":[{"given":"Luka","family":"Vitez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Marko","family":"Mihailovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojca","family":"Bo\u017ei\u010d Mijovski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Borut","family":"Jug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matja\u017e","family":"Bunc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"4635","DOI":"10.1093\/eurheartj\/ehaf194","article-title":"2025 ESC\/EACTS Guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"46","author":"Praz","year":"2025","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.4244\/EIJ-D-20-00303","article-title":"Clinical outcomes of TAVI or SAVR in men and women with aortic stenosis at intermediate operative risk: a post hoc analysis of the randomised SURTAVI trial","volume":"16","author":"Van Mieghem","year":"2020","journal-title":"EuroIntervention"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1514616","article-title":"Transcatheter or surgical aortic-valve replacement in intermediate-risk patients","volume":"374","author":"Leon","year":"2016","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2307447","article-title":"Transcatheter aortic-valve replacement in low-risk patients at five years","volume":"389","author":"Mack","year":"2023","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.jacc.2023.09.813","article-title":"4-year outcomes of patients with aortic stenosis in the evolut low risk trial","volume":"82","author":"Forrest","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.4244\/EIJY14M06_05","article-title":"Occurrence and prognostic impact of systemic inflammatory response syndrome in transfemoral and transapical aortic valve implantation with balloon- and self-expandable valves","volume":"10","author":"Schwietz","year":"2015","journal-title":"EuroIntervention"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1093\/eurheartj\/ehs002","article-title":"Systemic inflammatory response syndrome predicts increased mortality in patients after transcatheter aortic valve implantation","volume":"33","author":"Sinning","year":"2012","journal-title":"Eur Heart J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.carrev.2023.11.019","article-title":"Systemic inflammatory response syndrome in patients undergoing transcatheter aortic valve implantation","volume":"62","author":"Syryca","year":"2024","journal-title":"Cardiovasc Revasc Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/ehf2.12837","article-title":"Inflammatory signatures are associated with increased mortality after transfemoral transcatheter aortic valve implantation","volume":"7","author":"Hoffmann","year":"2020","journal-title":"ESC Heart Failure"},{"key":"B10","doi-asserted-by":"publisher","first-page":"100761","DOI":"10.1016\/j.jacadv.2023.100761","article-title":"Multimarker approach to improve risk stratification of patients undergoing transcatheter aortic valve implantation","volume":"3","author":"Hecht","year":"2024","journal-title":"JACC: Advances"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3267","DOI":"10.3390\/jcm9103267","article-title":"Complexity of TNF-\u03b1 signaling in heart disease","volume":"9","author":"Rolski","year":"2020","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.cellimm.2009.09.006","article-title":"The ACE inhibitors enalapril and captopril modulate cytokine responses in balb\/c and C57Bl\/6 normal mice and increase CD4(+)CD103(+)CD25(negative) splenic T cell numbers","volume":"260","author":"Albuquerque","year":"2010","journal-title":"Cell Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00011-020-01382-6","article-title":"The role of interferon-\u03b3 in cardiovascular disease: an update","volume":"69","author":"Elyasi","year":"2020","journal-title":"Inflamm Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1357343","DOI":"10.3389\/fcvm.2024.1357343","article-title":"Interferons and interferon-related pathways in heart disease","volume":"11","author":"Tran","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1016\/j.jacc.2019.08.1039","article-title":"Clinical and prognostic significance of sST2 in heart failure: JACC review topic of the week","volume":"74","author":"Aimo","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1016\/j.jacc.2021.02.038","article-title":"Valve academic research consortium 3: updated endpoint definitions for aortic valve clinical research","volume":"77","author":"G\u00e9n\u00e9reux","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"746774","DOI":"10.3389\/fcvm.2021.746774","article-title":"Impact of systemic inflammatory response syndrome on clinical, echocardiographic, and computed tomographic outcomes among patients undergoing transcatheter aortic valve implantation","volume":"8","author":"Ahmed","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1136\/heartjnl-2014-307057","article-title":"Systemic inflammatory response syndrome after transcatheter or surgical aortic valve replacement","volume":"101","author":"Lindman","year":"2015","journal-title":"Heart"},{"key":"B21","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2459\/JCM.0000000000001309","article-title":"Prognostic value of systemic inflammatory response syndrome after transcatheter aortic valve implantation","volume":"23","author":"Monosilio","year":"2022","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1001\/archinte.165.14.1643","article-title":"Systemic inflammatory response syndrome after acute myocardial infarction complicated by cardiogenic shock","volume":"165","author":"Kohsaka","year":"2005","journal-title":"Arch Intern Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.amjcard.2004.11.008","article-title":"Prognostic usefulness of white blood cell count and temperature in acute myocardial infarction (from the CARDINAL trial)","volume":"95","author":"Patel","year":"2005","journal-title":"Am J Cardiol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1093\/eurheartj\/ehi292","article-title":"Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial","volume":"26","author":"Th\u00e9roux","year":"2005","journal-title":"Eur Heart J"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e0258963","DOI":"10.1371\/journal.pone.0258963","article-title":"Differential systemic inflammatory responses after TAVI: the role of self versus balloon expandable devices","volume":"16","author":"Abu Khadija","year":"2021","journal-title":"PLoS One"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e002430","DOI":"10.1161\/JAHA.115.002430","article-title":"Post-procedural troponin elevation and clinical outcomes following transcatheter aortic valve implantation","volume":"5","author":"Koskinas","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.4244\/EIJY15M02_02","article-title":"The prognostic value of acute and chronic troponin elevation after transcatheter aortic valve implantation","volume":"11","author":"Sinning","year":"2016","journal-title":"EuroIntervention"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e010742","DOI":"10.1161\/CIRCINTERVENTIONS.121.010742","article-title":"Ultrasound- versus fluoroscopy-guided strategy for transfemoral transcatheter aortic valve replacement access: a systematic review and meta-analysis","volume":"14","author":"Kotronias","year":"2021","journal-title":"Circ Cardiovasc Interv"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3390\/jcm13051514","article-title":"See it best: a propensity-matched analysis of ultrasound-guided versus blind femoral artery puncture in balloon-expandable TAVI","volume":"13","author":"Gennari","year":"2024","journal-title":"J Clin Med"},{"key":"B31","doi-asserted-by":"publisher","first-page":"107054","DOI":"10.1016\/j.jstrokecerebrovasdis.2023.107054","article-title":"Outcomes and predictors of periprocedural stroke after transcatheter aortic valve implantation","volume":"32","author":"Castelo","year":"2023","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"B32","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1093\/eurheartj\/ehae081","article-title":"Reducing length of stay after transfemoral transcatheter aortic valve implantation: the FAST-TAVI II trial","volume":"45","author":"Durand","year":"2024","journal-title":"Eur Heart J"},{"key":"B33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.jjcc.2017.11.007","article-title":"Mechanisms of aortic stenosis","volume":"71","author":"Akahori","year":"2018","journal-title":"J Cardiol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"140","DOI":"10.31083\/j.rcm2405140","article-title":"Improved endothelial and autonomic function after transcatheter aortic valve implantation","volume":"24","author":"Vitez","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"B35","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/ehjacc\/zuae148","article-title":"C-reactive protein levels and outcomes in infarct-related cardiogenic shock: data from the ECLS-SHOCK trial","volume":"14","author":"Schupp","year":"2025","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"B36","doi-asserted-by":"publisher","first-page":"16338","DOI":"10.1038\/s41598-024-67556-y","article-title":"The admission level of CRP during cardiogenic shock is a strong independent risk marker of mortality","volume":"14","author":"Roubille","year":"2024","journal-title":"Sci Rep"},{"key":"B37","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1093\/eurheartj\/ehae593","article-title":"Sex-specific prediction of cardiogenic shock after acute coronary syndromes: the SEX-SHOCK score","volume":"45","author":"Wang","year":"2024","journal-title":"Eur Heart J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/eurheartj\/ehaa099","article-title":"Targeting cardiovascular inflammation: next steps in clinical translation","volume":"42","author":"Lawler","year":"2021","journal-title":"Eur Heart J"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/j.jacc.2020.01.014","article-title":"Inflammation in heart failure","volume":"75","author":"Murphy","year":"2020","journal-title":"JACC"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1056\/NEJMoa2021372","article-title":"Colchicine in patients with chronic coronary disease","volume":"383","author":"Nidorf","year":"2020","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1161\/CIRCULATIONAHA.118.038010","article-title":"Anti-inflammatory therapy with canakinumab for the prevention of hospitalization for heart failure","volume":"139","author":"Everett","year":"2019","journal-title":"Circulation"},{"key":"B43","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1007\/s10741-013-9393-8","article-title":"Could interferon-gamma be a therapeutic target for treating heart failure?","volume":"19","author":"Levick","year":"2014","journal-title":"Heart Fail Rev"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1161\/ATVBAHA.108.179705","article-title":"Inflammation in atherosclerosis","volume":"32","author":"Libby","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1161\/CIRCINTERVENTIONS.122.012388","article-title":"Lifetime management of aortic stenosis: transcatheter versus surgical treatment for young and low-risk patients","volume":"15","author":"Russo","year":"2022","journal-title":"Circ Cardiovasc Interv"},{"key":"B46","doi-asserted-by":"publisher","first-page":"e018921","DOI":"10.1161\/JAHA.120.018921","article-title":"Noncalcific mechanisms of bioprosthetic structural valve degeneration","volume":"10","author":"Marro","year":"2021","journal-title":"J Am Heart Assoc"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1722293\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T06:29:12Z","timestamp":1767335352000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2025.1722293\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,2]]},"references-count":46,"alternative-id":["10.3389\/fcvm.2025.1722293"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2025.1722293","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,2]]},"article-number":"1722293"}}